The global Bacillus Calmette Guerin Vaccine Market growth is projected to reach US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Global Bacillus Calmette Guerin Vaccine Market Growth And Outlook 2025-31

The global Bacillus Calmette Guerin Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Bacillus Calmette Guerin Vaccine provides immunity or protection against tuberculosis (TB). The vaccine may be given to persons at high risk of developing TB. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the ?Bacillus Calmette Guerin Vaccine Industry Forecast? looks at past sales and reviews total world Bacillus Calmette Guerin Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Bacillus Calmette Guerin Vaccine sales for 2025 through 2031. With Bacillus Calmette Guerin Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bacillus Calmette Guerin Vaccine industry. This Insight Report provides a comprehensive analysis of the global Bacillus Calmette Guerin Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bacillus Calmette Guerin Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Bacillus Calmette Guerin Vaccine market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bacillus Calmette Guerin Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bacillus Calmette Guerin Vaccine. This report presents a comprehensive overview, market shares, and growth opportunities of Bacillus Calmette Guerin Vaccine market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Immune Type &nbsp;&nbsp;&nbsp; Therapy Type Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospitals &nbsp;&nbsp;&nbsp; Clinics &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; Sanofi Pasteur &nbsp;&nbsp;&nbsp; Japan BCG Lab &nbsp;&nbsp;&nbsp; China National Biotec &nbsp;&nbsp;&nbsp; AJ Vaccines &nbsp;&nbsp;&nbsp; Serum Institute of India &nbsp;&nbsp;&nbsp; Intervax &nbsp;&nbsp;&nbsp; GSBPL &nbsp;&nbsp;&nbsp; Statens Serum Institute &nbsp;&nbsp;&nbsp; Biomed Lublin &nbsp;&nbsp;&nbsp; ANLIS Malbran &nbsp;&nbsp;&nbsp; Funda?o Ataulpho de Paiva &nbsp;&nbsp;&nbsp; BB-NCIPD &nbsp;&nbsp;&nbsp; Taj Pharmaceuticals &nbsp;&nbsp;&nbsp; Bio Farma &nbsp;&nbsp;&nbsp; Microgen &nbsp;&nbsp;&nbsp; Torlakinstitut &nbsp;&nbsp;&nbsp; Institut Pasteur de Tunis &nbsp;&nbsp;&nbsp; IVAC Key Questions Addressed in this Report What is the 10-year outlook for the global Bacillus Calmette Guerin Vaccine market? What factors are driving Bacillus Calmette Guerin Vaccine market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Bacillus Calmette Guerin Vaccine market opportunities vary by end market size? How does Bacillus Calmette Guerin Vaccine break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Bacillus Calmette Guerin Vaccine Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Bacillus Calmette Guerin Vaccine by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Bacillus Calmette Guerin Vaccine by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Bacillus Calmette Guerin Vaccine Segment by Type &nbsp;2.2.1 Immune Type &nbsp;2.2.2 Therapy Type &nbsp;2.3 Bacillus Calmette Guerin Vaccine Sales by Type &nbsp;2.3.1 Global Bacillus Calmette Guerin Vaccine Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Bacillus Calmette Guerin Vaccine Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Bacillus Calmette Guerin Vaccine Sale Price by Type (2020-2025) &nbsp;2.4 Bacillus Calmette Guerin Vaccine Segment by Application &nbsp;2.4.1 Hospitals &nbsp;2.4.2 Clinics &nbsp;2.4.3 Others &nbsp;2.5 Bacillus Calmette Guerin Vaccine Sales by Application &nbsp;2.5.1 Global Bacillus Calmette Guerin Vaccine Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Bacillus Calmette Guerin Vaccine Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Bacillus Calmette Guerin Vaccine Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Bacillus Calmette Guerin Vaccine Breakdown Data by Company &nbsp;3.1.1 Global Bacillus Calmette Guerin Vaccine Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Bacillus Calmette Guerin Vaccine Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Bacillus Calmette Guerin Vaccine Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Bacillus Calmette Guerin Vaccine Revenue by Company (2020-2025) &nbsp;3.2.2 Global Bacillus Calmette Guerin Vaccine Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Bacillus Calmette Guerin Vaccine Sale Price by Company &nbsp;3.4 Key Manufacturers Bacillus Calmette Guerin Vaccine Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Bacillus Calmette Guerin Vaccine Product Location Distribution &nbsp;3.4.2 Players Bacillus Calmette Guerin Vaccine Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Bacillus Calmette Guerin Vaccine by Geographic Region &nbsp;4.1 World Historic Bacillus Calmette Guerin Vaccine Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Bacillus Calmette Guerin Vaccine Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Bacillus Calmette Guerin Vaccine Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Bacillus Calmette Guerin Vaccine Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Bacillus Calmette Guerin Vaccine Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Bacillus Calmette Guerin Vaccine Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Bacillus Calmette Guerin Vaccine Sales Growth &nbsp;4.4 APAC Bacillus Calmette Guerin Vaccine Sales Growth &nbsp;4.5 Europe Bacillus Calmette Guerin Vaccine Sales Growth &nbsp;4.6 Middle East & Africa Bacillus Calmette Guerin Vaccine Sales Growth 5 Americas &nbsp;5.1 Americas Bacillus Calmette Guerin Vaccine Sales by Country &nbsp;5.1.1 Americas Bacillus Calmette Guerin Vaccine Sales by Country (2020-2025) &nbsp;5.1.2 Americas Bacillus Calmette Guerin Vaccine Revenue by Country (2020-2025) &nbsp;5.2 Americas Bacillus Calmette Guerin Vaccine Sales by Type (2020-2025) &nbsp;5.3 Americas Bacillus Calmette Guerin Vaccine Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Bacillus Calmette Guerin Vaccine Sales by Region &nbsp;6.1.1 APAC Bacillus Calmette Guerin Vaccine Sales by Region (2020-2025) &nbsp;6.1.2 APAC Bacillus Calmette Guerin Vaccine Revenue by Region (2020-2025) &nbsp;6.2 APAC Bacillus Calmette Guerin Vaccine Sales by Type (2020-2025) &nbsp;6.3 APAC Bacillus Calmette Guerin Vaccine Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Bacillus Calmette Guerin Vaccine by Country &nbsp;7.1.1 Europe Bacillus Calmette Guerin Vaccine Sales by Country (2020-2025) &nbsp;7.1.2 Europe Bacillus Calmette Guerin Vaccine Revenue by Country (2020-2025) &nbsp;7.2 Europe Bacillus Calmette Guerin Vaccine Sales by Type (2020-2025) &nbsp;7.3 Europe Bacillus Calmette Guerin Vaccine Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Bacillus Calmette Guerin Vaccine by Country &nbsp;8.1.1 Middle East & Africa Bacillus Calmette Guerin Vaccine Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Bacillus Calmette Guerin Vaccine Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Bacillus Calmette Guerin Vaccine Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Bacillus Calmette Guerin Vaccine Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Bacillus Calmette Guerin Vaccine &nbsp;10.3 Manufacturing Process Analysis of Bacillus Calmette Guerin Vaccine &nbsp;10.4 Industry Chain Structure of Bacillus Calmette Guerin Vaccine 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Bacillus Calmette Guerin Vaccine Distributors &nbsp;11.3 Bacillus Calmette Guerin Vaccine Customer 12 World Forecast Review for Bacillus Calmette Guerin Vaccine by Geographic Region &nbsp;12.1 Global Bacillus Calmette Guerin Vaccine Market Size Forecast by Region &nbsp;12.1.1 Global Bacillus Calmette Guerin Vaccine Forecast by Region (2026-2031) &nbsp;12.1.2 Global Bacillus Calmette Guerin Vaccine Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Bacillus Calmette Guerin Vaccine Forecast by Type (2026-2031) &nbsp;12.7 Global Bacillus Calmette Guerin Vaccine Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Merck &nbsp;13.1.1 Merck Company Information &nbsp;13.1.2 Merck Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.1.3 Merck Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Merck Main Business Overview &nbsp;13.1.5 Merck Latest Developments &nbsp;13.2 Sanofi Pasteur &nbsp;13.2.1 Sanofi Pasteur Company Information &nbsp;13.2.2 Sanofi Pasteur Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.2.3 Sanofi Pasteur Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Sanofi Pasteur Main Business Overview &nbsp;13.2.5 Sanofi Pasteur Latest Developments &nbsp;13.3 Japan BCG Lab &nbsp;13.3.1 Japan BCG Lab Company Information &nbsp;13.3.2 Japan BCG Lab Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.3.3 Japan BCG Lab Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Japan BCG Lab Main Business Overview &nbsp;13.3.5 Japan BCG Lab Latest Developments &nbsp;13.4 China National Biotec &nbsp;13.4.1 China National Biotec Company Information &nbsp;13.4.2 China National Biotec Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.4.3 China National Biotec Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 China National Biotec Main Business Overview &nbsp;13.4.5 China National Biotec Latest Developments &nbsp;13.5 AJ Vaccines &nbsp;13.5.1 AJ Vaccines Company Information &nbsp;13.5.2 AJ Vaccines Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.5.3 AJ Vaccines Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 AJ Vaccines Main Business Overview &nbsp;13.5.5 AJ Vaccines Latest Developments &nbsp;13.6 Serum Institute of India &nbsp;13.6.1 Serum Institute of India Company Information &nbsp;13.6.2 Serum Institute of India Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.6.3 Serum Institute of India Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Serum Institute of India Main Business Overview &nbsp;13.6.5 Serum Institute of India Latest Developments &nbsp;13.7 Intervax &nbsp;13.7.1 Intervax Company Information &nbsp;13.7.2 Intervax Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.7.3 Intervax Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Intervax Main Business Overview &nbsp;13.7.5 Intervax Latest Developments &nbsp;13.8 GSBPL &nbsp;13.8.1 GSBPL Company Information &nbsp;13.8.2 GSBPL Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.8.3 GSBPL Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 GSBPL Main Business Overview &nbsp;13.8.5 GSBPL Latest Developments &nbsp;13.9 Statens Serum Institute &nbsp;13.9.1 Statens Serum Institute Company Information &nbsp;13.9.2 Statens Serum Institute Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.9.3 Statens Serum Institute Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Statens Serum Institute Main Business Overview &nbsp;13.9.5 Statens Serum Institute Latest Developments &nbsp;13.10 Biomed Lublin &nbsp;13.10.1 Biomed Lublin Company Information &nbsp;13.10.2 Biomed Lublin Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.10.3 Biomed Lublin Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Biomed Lublin Main Business Overview &nbsp;13.10.5 Biomed Lublin Latest Developments &nbsp;13.11 ANLIS Malbran &nbsp;13.11.1 ANLIS Malbran Company Information &nbsp;13.11.2 ANLIS Malbran Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.11.3 ANLIS Malbran Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 ANLIS Malbran Main Business Overview &nbsp;13.11.5 ANLIS Malbran Latest Developments &nbsp;13.12 Funda�?o Ataulpho de Paiva &nbsp;13.12.1 Funda�?o Ataulpho de Paiva Company Information &nbsp;13.12.2 Funda�?o Ataulpho de Paiva Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.12.3 Funda�?o Ataulpho de Paiva Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Funda�?o Ataulpho de Paiva Main Business Overview &nbsp;13.12.5 Funda�?o Ataulpho de Paiva Latest Developments &nbsp;13.13 BB-NCIPD &nbsp;13.13.1 BB-NCIPD Company Information &nbsp;13.13.2 BB-NCIPD Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.13.3 BB-NCIPD Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 BB-NCIPD Main Business Overview &nbsp;13.13.5 BB-NCIPD Latest Developments &nbsp;13.14 Taj Pharmaceuticals &nbsp;13.14.1 Taj Pharmaceuticals Company Information &nbsp;13.14.2 Taj Pharmaceuticals Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.14.3 Taj Pharmaceuticals Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Taj Pharmaceuticals Main Business Overview &nbsp;13.14.5 Taj Pharmaceuticals Latest Developments &nbsp;13.15 Bio Farma &nbsp;13.15.1 Bio Farma Company Information &nbsp;13.15.2 Bio Farma Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.15.3 Bio Farma Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Bio Farma Main Business Overview &nbsp;13.15.5 Bio Farma Latest Developments &nbsp;13.16 Microgen &nbsp;13.16.1 Microgen Company Information &nbsp;13.16.2 Microgen Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.16.3 Microgen Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.16.4 Microgen Main Business Overview &nbsp;13.16.5 Microgen Latest Developments &nbsp;13.17 Torlakinstitut &nbsp;13.17.1 Torlakinstitut Company Information &nbsp;13.17.2 Torlakinstitut Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.17.3 Torlakinstitut Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.17.4 Torlakinstitut Main Business Overview &nbsp;13.17.5 Torlakinstitut Latest Developments &nbsp;13.18 Institut Pasteur de Tunis &nbsp;13.18.1 Institut Pasteur de Tunis Company Information &nbsp;13.18.2 Institut Pasteur de Tunis Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.18.3 Institut Pasteur de Tunis Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.18.4 Institut Pasteur de Tunis Main Business Overview &nbsp;13.18.5 Institut Pasteur de Tunis Latest Developments &nbsp;13.19 IVAC &nbsp;13.19.1 IVAC Company Information &nbsp;13.19.2 IVAC Bacillus Calmette Guerin Vaccine Product Portfolios and Specifications &nbsp;13.19.3 IVAC Bacillus Calmette Guerin Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.19.4 IVAC Main Business Overview &nbsp;13.19.5 IVAC Latest Developments 14 Research Findings and Conclusion

Report	Global Bacillus Calmette Guerin Vaccine Market Growth 2025-2031
Selected License	Multi ID: LPI9818

Buyer Information

Order Summary